This is a working overview of Synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-10. Anything still debated is marked as such rather than presented as settled.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Barotrauma is physical damage to body tissues caused by a difference in pressure between a gas space inside, or in contact with, the body and the surrounding gas or liquid. The initial damage is usually due to over-stretching the tissues in tension or shear, either directly by an expansion of the gas in the closed space or by pressure difference hydrostatically transmitted through the tissue. Tissue rupture may be complicated by the introduction of gas into the local tissue or circulation through the initial trauma site, which can cause blockage of circulation at distant sites or interfere with the normal function of an organ by its presence. The term is usually applied when the gas volume involved already exists prior to decompression. Barotrauma can occur during both compression and decompression events. Barotrauma generally manifests as sinus or middle ear effects, lung overpressure injuries and injuries resulting from external squeezes. Decompression sickness is indirectly caused by ambient pressure reduction, and tissue damage is caused directly and indirectly by gas bubbles. However, these bubbles form out of supersaturated solution from dissolved gases, and are not generally considered barotrauma. Decompression illness is a term that includes decompression sickness and arterial gas embolism caused by lung overexpansion barotrauma. It is also classified under the broader term of dysbarism, which covers all medical conditions resulting from changes in ambient pressure.
== External links == What is a WW domain? Ranganathan lecture on statistical coupling analysis (audio included) Protein folding — a step closer? - A summary of the Ranganathan lab's SCA-based design of artificial yet functional WW domains.
Member American Academy of Arts & Sciences (2025) Member, The World Academy of Science (2025) Founders Award, Controlled Release Society (2025) Distinguished Scientist Award, American Association of Pharmaceutical Scientists (2024) Doing a World of Good Medal (2023) BIOS- Top 50 Lifescience Entrepreneur List (2022) Kydonieus Award, Controlled Release Society (2020) Clemson Award, Society for Biomaterials (2017) Member, National Academy of Medicine (NAM) (2016) Fellow, Biomedical Engineering Society (BMES) (2015) Fellow, American Association of Pharmaceutical Scientists (AAPS) (2015) Fellow, Controlled Release Society (CRS) (2015) Andreas Acrivos Award for Professional Progress, American Institute of Chemical Engineers (AIChE) (2015) Member, National Academy of Engineering (NAE) (2015) Fellow, National Academy of Inventors (NAI) (2013) Fellow, American Association for the Advancement of Science (AAAS) (2012) Fellow, American Institute for Medical and Biological Engineering (AIMBE) (2010) Controlled Release Society’s Young Scientist Award (2008) American Institute of Chemical Engineers Allan P. Colburn award (2005) Selection by MIT's Technology Review Magazine as one of the world's top Innovators Under 35 (1999)
Sources: en.wikipedia.org
=== Twentieth century === Beak trimming was developed at the Ohio Agricultural Experiment Station in the 1930s. The original technique was temporary, cutting approximately 6 mm (1/4 inch) off the beak. It was thought that the tip of the beak had no blood supply and presumably no sensation. The procedure was performed by hand with a sharp knife, either when deaths due to cannibalism became excessive, or when the problem was anticipated because of a history of cannibalism in the particular strain of chicken. Cannibalism is a serious management problem dating back to the periods before intensive housing of poultry became popular. Poultry books written before vertical integration of the poultry industry describe the abnormal pecking of poultry:
Computer-based methods for predicting the binding orientation and affinity of an inhibitor for an enzyme such as molecular docking and molecular mechanics can be used to assist in the optimisation process. New inhibitors are used to obtain crystallographic structures of the enzyme in an inhibitor/enzyme complex to show how the molecule is binding to the active site, allowing changes to be made to the inhibitor to optimise binding in a process known as structure-based drug design. This test and improve cycle is repeated until a sufficiently potent inhibitor is produced.
=== Chairmen === R.S. Sharma, 1972 - 1977 A.R. Kulkarni, 1978 - 1981 Niharranjan Ray, 1981 - 1981 Lokesh Chandra, 1982 - 1985 Irfan Habib, 1986 - 1993 Ravinder Kumar, 1993 - 1996 S. Settar, 1996 - 1999 K.S. Sarma (acting), 1999 - 1999 B.R. Grover, 1999 - 2001 K.S. Lal, 2001 - 2001 M.G.S. Narayanan, 2001 - 2003 Kumud Bansal (acting), 2003 - 2004 D.N. Tripathi, 2004 - 2007 K.M. Acharya (acting), 2007 - 2007 Sabyasachi Bhattacharya, 4 March 2007 – 3 March 2010 Sabyasachi Bhattacharya (acting), 4 April 2010 – 20 May 2011 Basudev Chatterjee, 20 May 2011 - 2014 Yellapragada Sudershan Rao, 28 June 2014 - 26 June 2017 A.P Jamkhedkar, 15 February 2018 – 14 January 2022 Raghuvendra Tanwar, 14 January 2022 - present
Later she drew a distinction between their methods, arguing that Quimby's involved one mind healing another, while hers depended on a connection with Divine Mind. In February 1883, Julius Dresser, a former patient of Quimby's, accused Eddy in letters to The Boston Post of teaching Quimby's work as her own. In response Eddy disparaged Quimby as a mesmerist and said she had experimented with mental healing in or around 1853, nine years before she met him. She wrote later: "We caught some of his thoughts, and he caught some of ours; and both of us were pleased to say this to each other." The issue went to court in September 1883, when Eddy complained that her student Edward Arens had copied parts of Science and Health in a pamphlet, and Arens counter-claimed that Eddy had copied it from Quimby in the first place. Quimby's son was so unwilling to produce his father's manuscripts that he sent them out of the country (perhaps fearing litigation with Eddy or that someone would tamper with them), and Eddy won the case. Things were stirred up further by Eddy's pamphlet Historical Sketch of Metaphysical Healing (1885), in which she again called Quimby a mesmerist, and by the publication of Julius Dresser's The True History of Mental Healing (1887). The charge that Christian Science came from Quimby, not divine revelation, stemmed in part from Eddy's use of Quimby's manuscript (right) when teaching Sally Wentworth and others in 1868–1870. Eddy said she had helped to fix Quimby's unpublished work, and now stood accused of having copied her own corrections. Against this, Lyman P.
Sources: en.wikipedia.org
Reversible inhibitors attach to enzymes with non-covalent interactions such as hydrogen bonds, hydrophobic interactions and ionic bonds. Multiple weak bonds between the inhibitor and the enzyme active site combine to produce strong and specific binding. In contrast to irreversible inhibitors, reversible inhibitors generally do not undergo chemical reactions when bound to the enzyme and can be easily removed by dilution or dialysis. A special case is covalent reversible inhibitors that form a chemical bond with the enzyme, but the bond can be cleaved so the inhibition is fully reversible. Reversible inhibitors are generally categorized into four types, as introduced by Cleland in 1963. They are classified according to the effect of the inhibitor on the Vmax (maximum reaction rate catalysed by the enzyme) and Km (the concentration of substrate resulting in half maximal enzyme activity) as the concentration of the enzyme's substrate is varied.
As the arteriosclerosis progresses, blood flows less easily through rigid and narrowed blood vessels, making the blood more likely to form a thrombosis (clot). Sudden blockage of a blood vessel may lead to an infarction (stroke or heart attack). However, the effects of smoking on the heart may be more subtle. These conditions may develop gradually, given the smoking–healing cycle (the human body heals itself between periods of smoking). Therefore, a person who smokes may develop less significant disorders, such as worsening or maintenance of unpleasant dermatological conditions, e.g., eczema, due to reduced blood supply. Smoking also increases blood pressure and weakens blood vessels.
In the cooking process, Maillard reactions can produce hundreds of different flavor compounds depending on the chemical constituents in the food, the temperature, the cooking time, and the presence of air. These compounds, in turn, often break down to form yet more flavor compounds. Flavorists have used the Maillard reaction over the years to make artificial flavors, the majority of patents being related to the production of meat-like flavors. According to chemistry Nobel Prize winner Jean-Marie Lehn "The Maillard is, by far, the most widely practiced chemical reaction in the world".
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.